Search IPOs
GOLDLINE · BSE · Pharmaceutical
Goldline Pharmaceutical IPO listed on 19 May 2026 on BSE at ₹59.75, a gain of 38.95% over the issue price of ₹43.00. The IPO was subscribed 840.74x overall.
Goldline Pharmaceutical IPO tentative timeline covering IPO opening, closing, basis of allotment, refunds, demat credit, and listing dates.
| Event | Date |
|---|---|
| IPO Open Date | 12 May 2026 |
| IPO Close Date | 14 May 2026 |
| Basis of Allotment | 15 May 2026 |
| Initiation of Refunds | 18 May 2026 |
| Credit of Shares to Demat | 18 May 2026 |
| Listing Date | 19 May 2026 |
Listing day gain
+38.95%
Listed at ₹59.75 (issue ₹43)
Issue
₹43
Listing
₹59.75
Current
₹56.77
+32.02% vs issue
Day range
₹56.77 – ₹60
Issue Size
2,700,000 shares
(aggregating up to ₹12.00 Cr)
Issue Price
₹41 – ₹43
Face Value
₹10/share
Market Lot
3,000 shares
Retail Min Investment
₹258,000
Listing At
BSE
Sale Type
fresh issue
Fresh Issue
2,562,000 shares
(aggregating up to ₹11 Cr)
Offer for Sale
[.]
Reserved for Market Maker
138,000 shares
(aggregating up to ₹0.60 Cr)
Issue Type
book building
Open Date
12 May
Close Date
14 May
Allotment
15 May
Listing
19 May
Last updated: 4 months ago
| Date | IPO Issue Price (₹) | GMP (₹) | Est. Listing Price (₹) | Est. Profit Amount (₹) | Est. Profit % | Last Updated |
|---|---|---|---|---|---|---|
| 19 May 2026 Latest | ₹43 | ₹15 | ₹58 | ₹15 |
34.88%
|
11:25 AM |
| 18 May 2026 | ₹43 | ₹15 | ₹58 | ₹15 |
34.88%
|
12:02 PM |
Showing the 2 most recent GMP entries.
View full GMP historyLatest snapshot: 14 May 2026
| Category | Subscribed (x) | No. of Applications |
|---|---|---|
| QIB | 180.22x | - |
| NII | 1,662.04x | - |
| bNII (bids above ₹10L) | 1,995.14x | - |
| sNII (bids below ₹10L) | 995.84x | - |
| Individual Investors | 881.15x | - |
| Total | 840.74x | - |
Showing the latest subscription snapshot.
View full subscription historyAmol Laxmikant Mujumdar and Swapan Premprakash Khandelwal are the promoters.
New to lot sizes and investment limits? Read our guide on IPO lot size and minimum investment.
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 2 | 6,000 | ₹258,000 |
| Retail (Max) | 2 | 6,000 | ₹258,000 |
| S-HNI (Min) | 3 | 9,000 | ₹387,000 |
| S-HNI (Max) | 7 | 21,000 | ₹903,000 |
| B-HNI (Min) | 8 | 24,000 | ₹1,032,000 |
Want to understand how IPO shares are divided between investor categories? Read our guide on IPO reservation structure.
| Category | Shares Offered |
|---|---|
| QIB Shares Offered | 1,272,000 (47.11%) |
|
•
Anchor Investor Shares Offered
|
732,000 (27.11%) |
|
•
QIB (Ex. Anchor) Shares Offered
|
540,000 (20.00%) |
| Market Maker Shares Offered | 138,000 (5.11%) |
| Individual Investors Shares Offered | 900,000 (33.67%) |
| NII (HNI) Shares Offered | 390,000 (14.11%) |
| Total Shares Offered | 2,700,000 (100.00%) |
Goldline Pharmaceutical Limited has a pretty simple origin story. Mr. Amol Mujumdar, a pharmacy graduate with hands-on pharma marketing experience, wanted to build something of his own. In 2004, he did exactly that — registered the company in Nagpur, Maharashtra, and got to work.
The business focuses on generic medicines — the kind that actually reach people in smaller towns and semi-urban markets. Over the years, the company spread its presence across nine states including Maharashtra, Madhya Pradesh, Chhattisgarh, Rajasthan, Tamil Nadu, Goa, and a few more. That kind of reach doesn't happen overnight. It's built through distributor relationships, field teams, and consistent product availability on the ground.
Mr. Swapan Khandelwal joined the leadership in 2010, and together the two have kept the business steady in a fiercely competitive generics market. The product portfolio covers antibiotics, gastrointestinal medicines, protein supplements, and more — with several in-house formulations launched under their own brand names.
Standalone · ₹ in Crores
| Particulars | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Total Revenue | 19.85 | 23.57 | 28.06 |
| Profit After Tax (PAT) | 0.26 | 1.81 | 2.83 |
| EBITDA | 2.19 | 4.3 | 5.83 |
| Total Assets | 19.39 | 22.93 | 26.28 |
| Net Worth | 5.89 | 7.87 | 10.35 |
| Reserves & Surplus | 2.08 | 3.76 | 1.65 |
| Total Borrowing | 10.83 | 11.13 | 11.03 |
Revenue & Profit Trend
The basis of allotment for Goldline Pharmaceutical IPO was finalised on 15 May 2026. You can check your allotment status using your PAN number or application number on the Bigshare Services Private Limited portal or BSE.
The Goldline Pharmaceutical IPO is expected to open in May 2026, subject to SEBI approval. Final dates will be updated once announced officially.
The price band for Goldline Pharmaceutical IPO is ₹41.00 - ₹43.00 per share.
As per market sources, Goldline Pharmaceutical IPO GMP is currently ₹15.00. GMP is tracked daily in the grey market. GMP indicates unofficial demand but does not guarantee listing gains.
The subscription status for Goldline Pharmaceutical IPO stands at 840.74x overall.
The listing date for Goldline Pharmaceutical IPO is 19 May 2026.
No comments yet. Be the first to comment!
